CSPC PHARMA (01093.HK): SYS6088 trispecific antibody gets CT nod
- The antibody binds PD-1 and CTLA-4 on T-cell membranes and VEGFA in the tumour microenvironment, reversing T-cell exhaustion and inhibiting angiogenesis.
- Fc engineering lowers its toxicity risk and extends its half-life.
NewTimeSpace News: On 15 October 2026, CSPC Pharmaceutical Group Limited (01093.HK) announced that SYS6088 Injection, developed by the Group, has been approved by the National Medical Products Administration of the PRC for clinical trials in China. The product is a recombinant humanised PD-1, VEGFA and CTLA-4 trispecific antibody that binds to PD-1 and CTLA-4 on T-cell membranes and VEGFA in the tumour microenvironment, reversing T-cell exhaustion, restoring T-cell killing and inhibiting angiogenesis while promoting T-cell activation, delivering a triple synergistic anti-tumour effect. Fc engineering lowers its toxicity risk and extends its half-life. The approved indication is advanced or metastatic solid tumours. Preclinical studies showed broad indications with significant anti-tumour activity and a good safety profile.
- CSPC PHARMA (01093.HK): SYS6062 ADC gets China clinical trial nod
- CSPC PHARMA (01093.HK): Phase I Data for SYS6002 in Advanced Cervical Cancer; Confirmed ORR Up to 35.9%
- CSPC PHARMA (01093.HK): 8 trials to feature at ESMO 2026, two as LBAs
- CSPC PHARMA (01093.HK): Efmedaglutide Alfa Phase III Data at EASD 2026
- CSPC PHARMA (01093.HK): JMT206 Phase Ib Obesity Trial Starts in China
